argenx SE Stock price Nasdaq

Equities

ARGX

US04016X1019

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:51 2024-02-23 pm EST 5-day change 1st Jan Change
409.5 USD +0.86% Intraday chart for argenx SE +4.41% +7.64%
Sales 2023 * 1.11B 1.2B Sales 2024 * 1.62B 1.75B Capitalization 22.35B 24.18B
Net income 2023 * -245M -265M Net income 2024 * -108M -117M EV / Sales 2023 * 18 x
Net cash position 2023 * 2.37B 2.56B Net cash position 2024 * 2.35B 2.55B EV / Sales 2024 * 12.3 x
P/E ratio 2023 *
-88.3 x
P/E ratio 2024 *
-218 x
Employees 843
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.85%
More Fundamentals * Assessed data
Dynamic Chart
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday MT
Argenx Says FDA Accepted for Priority Review Supplemental BLA for Autoimmune Disease Drug Vyvgart Hytrulo MT
US FDA Accepts for Priority Review Argenx's Biologics License Application for Vyvgart Hytrulo MT
Argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy CI
Wolfe Research Starts Argenx With Peer Perform Rating MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Thursday Trading MT
Piper Sandler Adjusts argenx's Price Target to $518 From $515, Keeps Overweight Rating MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
Halozyme Therapeutics Says Argenx Gets Japan's Approval for Vyvdura to Treat Certain Generalized Myasthenia Gravis Patients MT
Argenx Says Japan Approved Vyvdura Injection for Generalized Myasthenia Gravis MT
Japanese Health Regulator Approves Argenx's Generalized Myasthenia Gravis Treatment MT
More news
1 day+0.86%
1 week+4.41%
Current month+7.62%
1 month+11.36%
3 months-17.24%
6 months-19.28%
Current year+7.64%
More quotes
1 week
393.56
Extreme 393.56
413.10
1 month
374.64
Extreme 374.64
413.10
Current year
359.24
Extreme 359.235
416.91
1 year
327.73
Extreme 327.725
550.76
3 years
248.21
Extreme 248.21
550.76
5 years
103.75
Extreme 103.75
550.76
10 years
17.33
Extreme 17.33
550.76
More quotes
Managers TitleAgeSince
Founder 52 07-12-31
Director of Finance/CFO 54 21-06-29
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 71 17-04-25
Director/Board Member 73 15-05-12
Director/Board Member 62 16-04-27
More insiders
Date Price Change Volume
24-02-23 409.5 +0.86% 160,785
24-02-22 406 +1.52% 308,108
24-02-21 400 +1.15% 433,053
24-02-20 395.4 +0.81% 311,975
24-02-16 392.2 -0.32% 187,625

Delayed Quote Nasdaq, February 23, 2024 at 03:59 pm EST

More quotes
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
377.6 EUR
Average target price
437 EUR
Spread / Average Target
+15.72%
Consensus
1st Jan change Capi.
+7.64% 24 182 M $
+5.71% 111 B $
+11.72% 105 B $
-10.96% 22 338 M $
-26.36% 21 352 M $
-6.59% 19 088 M $
-14.01% 16 173 M $
+1.84% 13 352 M $
+41.59% 12 772 M $
+1.18% 12 217 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock argenx SE
  4. Stock argenx SE - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer